20.500.12556/DiRROS-27324 Characteristics and predictors of clinical outcome in patients with pleural effusions caused by heart, liver and renal failure: results from the ERS International Multicentre Pleural Research Collaborative (IMPACT) registry Introduction Pleural effusions caused by organ dysfunction are the commonest pleural disease and account for a huge healthcare burden. Previous work has demonstrated poor survival rates, but there is still uncertainty about determinants of prognosis. This study describes the characteristics and risk factors for poor outcomes in patients with pleural effusion secondary to organ failure in an international cohort. Methods The European Respiratory Society International Multicentre Pleural Research Collaborative (IMPACT) registry includes an international retrospective study of patients with effusions secondary to heart, liver or renal failure, collected from 10 countries in Europe and North and South America between 2019 and 2021. The data were analysed for associations between baseline patient characteristics and key clinical outcomes. Descriptive data were collected on treatments and complications. Results A total of 755 patients contributed data. Overall, 85.2% of effusions were classified as transudates by Light's criteria. 42% of effusions were bilateral. One-year mortality rates were 46% in renal, 35% in hepatic and 33% in cardiac effusions. Increased mortality was observed in neutrophil-predominant effusions (HR 2.001, 95% CI 1.202–3.349, p=0.008), with age (HR 1.013, 95 CI 1.002–1.024, p=0.02) and with N-terminal pro-brain natriuretic peptide >450 pg·mL−1 (HR 1.508, 95% CI 1.191–1.911) in patients with cardiac failure. Therapeutic thoracentesis was the most frequently employed pleural intervention; indwelling pleural catheter use was rare and associated with higher pleural infection rates than thoracentesis. Conclusion This study identifies prognostic factors in an international cohort of patients with transudative pleural effusions. Identification of these risk factors may support treatment approaches in a global population. true false true European Respiratory Society ERJ open research Angleški jezik Ni določen ©The authors 2025 This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. Neznano 2026-02-02 08:33:12 2026-02-02 08:33:13 2026-02-04 03:45:17 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Soavtorja iz Slovenije: Aleš Rozman, Mateja Marc-Malovrh; Opis vira z dne 17. 12. 2025; 10 str. issue 6 Vol. 11 Nov. 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 2025-03-06 2025-11-29 2025-12-01 616.25-003.217 2312-0541 10.1183/23120541.00169-2025 261810947 https://publications.ersnet.org/content/erjor/11/6/00169-2025 1 73840dc5-0009-11f1-93b0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=39904 RAZ_Welch_Hugh_2025.pdf RAZ_Welch_Hugh_2025.pdf 1 1CDB11D17D688BC4C0EEF39E2328D6F5 5f12f50b316c31ea334bf365582671a39fceb85f2fc353d91d671a5bfe8402e9 5a4f3243-000a-11f1-93b0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=39905 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0